Coherus Oncology CHRS
NASDAQ CHRS
$1.35 +0.02 (+1.89%)
As of: Sep 10, 2026 · 3:59 PM EDT

Coherus Oncology (CHRS) EPS (Basic) Growth (5y) (2018 - 2026)

Analysis

Coherus Oncology (CHRS) EPS (Basic) Growth (5y) (2018 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn
10 Coherus Oncology 209.00 Mn 103.70 Mn 10.07 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 19.56%
Mar 31, 2026 34.74%
Dec 31, 2025 -34.32%
Sep 30, 2025 -22.45%
Jun 30, 2025 23.89%
Mar 31, 2025 -24.32%
Dec 31, 2024 -22.74%
Sep 30, 2024 -16.34%
Jun 30, 2024 -18.45%
Mar 31, 2024 38.81%
Dec 31, 2023 2.55%
Sep 30, 2023 14.10%
Jun 30, 2023 6.38%
Mar 31, 2023 -5.26%
Dec 31, 2022 3.78%
Sep 30, 2022 -0.42%
Jun 30, 2022 10.89%
Mar 31, 2022 4.13%
Dec 31, 2021 19.65%
Sep 30, 2021 -17.69%